Skip to main content
SpringerPlus

Table 5 Univariate analysis of serum markers in patients with EGFR mutation status analysed for survival

From: Pretreatment levels of the serum biomarkers CEA, CYFRA 21–1, SCC and the soluble EGFR and its ligands EGF, TGF-alpha, HB-EGF in the prediction of outcome in erlotinib treated non-small-cell lung cancer patients

   

Progression-free survival

Overall survival

Univariate cox analysis

Markers

Levels

N

Me a (95% CI)

p b

Me a (95% CI)

p b

Progression

Death

HR

95% CI

p

HR

95% CI

p

EGFR mutation

 

11

8.6 (2.0 – 15.1)

 

12.6 (4.7 – 21.1)

 

1.00

  

1.00

  

Wild type

 

21

2.8 (2.0 – 3.6)

0.012

5.4 (4.2 – 6.6)

0.033

0.36

0.16 – 0.82

0.015

0.39

0.16 – 0.95

0.039

CEA

<5

8

3.1 (1.8 – 4.4)

 

4.2 (2.0 – 6.4)

 

1.00

  

1.00

  
 

≥5

12

2.8 (0.0 – 6.5)

0.237

10.2 (5.0 – 15.0)

0.004

0.55

0.2 – 1.5

0.243

0.21

0.07 – 0.7

0.008

sEGFR

<56.87

20

2.8 (1.7 – 3.8)

 

4.2 (1.0 – 7.4)

 

1.00

  

1.00

  
 

≥56.87

24

3.8 (0.8 – 6.7)

0.106

9.5 (6.1 – 12.9)

0.013

0.51

0.22 - 1.2

0.112

0.34

0.1 – 0.8

0.016

  1. Abbreviations: Me Median, HR Hazard Ratio, CI Confidence interval.
  2. aMonths; bp value calculated using the Log-Rank test.
Back to article page